ClinicalTrials.gg
CompletedNCT00736957Updated Jul 2, 2014Results posted

A Long-term Efficacy and Safety Study of Tramadol Hydrochloride Plus Acetaminophen (JNS013) in Japanese Participants With Chronic Pain

A Phase 3 interventional study of Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013) in Chronic Pain, sponsored by Janssen Pharmaceutical K.K.. Completed at 26 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-07-02.

Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
219
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies testing tramadol in Chronic Pain — 2 open to participants now, 2 under way, none of them phase 3. Tramadol · Chronic Pain.

Enrollment
7th of 10
219 · median 283
Started
2008
with 1 other
Phase 3
7 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
2 of 10
Janssen Pharmaceutical K.K.

Among the 10 studies testing tramadol in Chronic Pain, this one is the 7th largest by enrollment, is one of 2 that started in 2008, is one of 7 in phase 3, and was the 6th registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

2 of the 10 studies testing tramadol in Chronic Pain are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About tramadol

Tramadol: first FDA approval 1995 (ULTRAM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 487 Chronic Pain studies recruiting now, 240 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing tramadol in Chronic Pain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of tramadol hydrochloride plus acetaminophen (JNS013) with long term administration in participants with chronic pain.

Read the detailed description

This is an open-label (both physician and participant know the name of the study drug), non-randomized, multicenter (when more than one hospital or medical school team work on a medical research study) and long-term efficacy and safety study of JNS013 (combination of tramadol hydrochloride (TRAM) with acetaminophen [APAP]) in participants with chronic pain (aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain). This study consists of 4 periods; screening period: 1 week, treatment period I: 4 weeks, treatment period II: 48 weeks and follow-up period: 1 week. During Treatment Period I, restrictions on concomitant treatments will be established and the participants will be treated with one or two tablets of JNS013, four times daily for four weeks. During Treatment Period II, the participants will be treated for 48 weeks using the same dosing method and dose level for JNS013 as was used during Treatment Period I, permitting modifications to the concomitant drugs/therapies as during normal medical care. Throughout both Treatment Period I and Treatment Period II, the decision will be made to permit the participants to select to use either one or two tablets of JNS013 per dose according to the extent of the participant's pain and tolerability. The total duration of treatment period will be of 52 weeks. Efficacy will be assessed using change from baseline in Visual Analogue Scale for pain (VAS24) score at the pre-defined time point until Week 52. Participants safety will be monitored throughout the study.

03

Conditions studied

  • Chronic Pain

Browse trials for

Keywords

  • Chronic Pain
  • Acetaminophen
  • Tramadol
  • JNS013
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants whose pain cannot be controlled sufficiently with at least 14-day continuous treatment with identical oral non anti inflammatory drugs (NSAIDs) at a usual maximum dose during 3 months prior to this study
  • Ambulatory participants without need for any supportive device or assistance during daily life
  • Outpatients
  • Participants who do not plan to change the therapeutic policy and content of the medications for underlying disease during screening period to the end of Treatment Period I
  • Sustention of chronic pain due to Osteo Arthritis (OA), Low Back Pain (LBP), Rheumatoid Arthritis (RA), Neck Shoulder Arm Syndrome (NSAS), Diabetic Neuropathy (DN), Post herpetic Neuralgia (PHN) or other for at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Participants with conditions for which opioids are
  • Participants with conditions for which APAP are contraindicated
  • Participants with history of convulsion or the possibility of convulsive seizure
  • Participants with concurrent, previous, or possible alcohol dependence, drug dependence, or narcotic addiction
  • Pregnant Participants or those who may be pregnant, lactating mothers, and Participants who wish pregnancy during the study period.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
219 participants (actual)

Study arms

  • Experimental
    Tramadol HCL plus Acetaminophen

    Drug: Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)

Interventions

  • DrugTramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)

    Drug pages: Tramadol · Acetaminophen

    Tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg (JNS013) one or two tablets will be given orally four times daily (maximum dose is 8 tablets per day) for 4 weeks during treatment period 1 (restrictions on concomitant treatments will be established) and for 48 weeks during treatment period 2 (permitting modifications to the concomitant drugs/therapies). The dosing interval will be of at least 4 hours.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Visual Analogue Scale (VAS24) Score at Week 4

    Pain over the last 24 hours was assessed by using VAS score ranges from 0 millimeter (mm)=no pain to 100 mm=worst possible pain. An increase in score from baseline represented disease progression and decrease represented improvement.

    Time frame: Baseline and Week 4

  2. Change From Baseline in VAS24 Score at Week 52

    Pain over the last 24 hours was assessed by using VAS score ranges from 0 mm=no pain to 100 mm=worst possible pain. An increase in score from baseline represented disease progression and decrease represented improvement.

    Time frame: Baseline and Week 52

Secondary outcomes

  1. Number of Participants With Improvement From Baseline in VAS24 Score

    Pain over the last 24 hours was assessed by using VAS score ranges from 0 mm=no pain to 100 mm=worst possible pain. An increase in score from baseline represented disease progression and decrease represented improvement.

    Time frame: Week 4 and 52

  2. Pain Intensity Difference (PID) at Week 4

    PID is defined as the amount of change in the pain intensity at each evaluation time point (at 2 and 4 hours after the study drug dosing) from the baseline for each participant. Pain Intensity was evaluated on a 4-stage scale ranging from 3=severe pain to 0=no pain. PID ranges from -3 (the worst) to +3 (the most improved).

    Time frame: Week 4

  3. Pain Relief (PAR) Score at Week 4

    Pain relief was evaluated based on a 5-stage scale from 4 (complete relief) to 0 (no relief). An increase in score represented improvement and decrease represented disease progression

    Time frame: Week 4

  4. Pain Relief Combined With Pain Intensity Difference (PRID) at Week 4

    PRID was sum of the PID and PAR for each participant at each evaluation time point (2 hours after dosing, 4 hours after dosing). Pain Intensity was evaluated on a 4-stage scale ranges from 3=severe pain to 0=no pain and PID ranges from -3 (the worst) to +3 (the most improved). PAR ranges from 0 (no improved) to +4 (the most improved). PRID ranges from -3 (the worst) to +7 (the most improved).

    Time frame: Week 4

  5. Change From Baseline in Short Form-36 (SF-36) Score

    SF-36 is a metric for general health and Quality of Life (QOL), consists of 8 sub-scale indices related to health and QOL (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health). Each of the sub-scale scores ranged from 0 to 100, where higher values indicate a better health status or a better mental status.

    Time frame: Baseline, Week 4 and 52

07

Results

Posted Jun 20, 2013

Participant flow

Participant flow — Overall Study
MilestoneTramadol Hydrochloride Plus Acetaminophen (JNS013)
Started219
Treated190
Completed97
Not completed122
Withdrew: Adverse event43
Withdrew: Withdrawal by subject49
Withdrew: Violation of eligibility criteria2
Withdrew: Did not attend hospital appointments1
Withdrew: Not eligible for treatment period i22
Withdrew: Physician decision5

Outcome measures

PrimaryChange From Baseline in Visual Analogue Scale (VAS24) Score at Week 4

Pain over the last 24 hours was assessed by using VAS score ranges from 0 millimeter (mm)=no pain to 100 mm=worst possible pain. An increase in score from baseline represented disease progression and decrease represented improvement.

Time frame:
Baseline and Week 4
Reported as:
Mean · millimeter
Change From Baseline in Visual Analogue Scale (VAS24) Score at Week 4
millimeterTramadol Hydrochloride Plus Acetaminophen (JNS013)
Baseline65.80 ± 11.629
Change at Week 4-22.28 ± 21.189
PrimaryChange From Baseline in VAS24 Score at Week 52

Pain over the last 24 hours was assessed by using VAS score ranges from 0 mm=no pain to 100 mm=worst possible pain. An increase in score from baseline represented disease progression and decrease represented improvement.

Time frame:
Baseline and Week 52
Reported as:
Mean · millimeter
Change From Baseline in VAS24 Score at Week 52
millimeterTramadol Hydrochloride Plus Acetaminophen (JNS013)
Baseline65.80 ± 11.629
Change at Week 52-36.54 ± 21.936
SecondaryNumber of Participants With Improvement From Baseline in VAS24 Score

Pain over the last 24 hours was assessed by using VAS score ranges from 0 mm=no pain to 100 mm=worst possible pain. An increase in score from baseline represented disease progression and decrease represented improvement.

Time frame:
Week 4 and 52
Reported as:
Number · participants
Number of Participants With Improvement From Baseline in VAS24 Score
participantsTramadol Hydrochloride Plus Acetaminophen (JNS013)
Improvement of 30 percent or more at Week 476
Improvement of 50 percent or more at Week 451
Improvement of 30 percent or more at Week 52110
Improvement of 50 percent or more at Week 5277
SecondaryPain Intensity Difference (PID) at Week 4

PID is defined as the amount of change in the pain intensity at each evaluation time point (at 2 and 4 hours after the study drug dosing) from the baseline for each participant. Pain Intensity was evaluated on a 4-stage scale ranging from 3=severe pain to 0=no pain. PID ranges from -3 (the worst) to +3 (the most improved).

Time frame:
Week 4
Reported as:
Mean · units on a scale
Pain Intensity Difference (PID) at Week 4
units on a scaleTramadol Hydrochloride Plus Acetaminophen (JNS013)
2 hours after dosing at Week 40.1 ± 0.35
4 hours after dosing at Week 40.1 ± 0.44
SecondaryPain Relief (PAR) Score at Week 4

Pain relief was evaluated based on a 5-stage scale from 4 (complete relief) to 0 (no relief). An increase in score represented improvement and decrease represented disease progression

Time frame:
Week 4
Reported as:
Mean · units on a scale
Pain Relief (PAR) Score at Week 4
units on a scaleTramadol Hydrochloride Plus Acetaminophen (JNS013)
2 hours after dosing at Week 41.3 ± 0.91
4 hours after dosing at Week 41.3 ± 0.99
SecondaryPain Relief Combined With Pain Intensity Difference (PRID) at Week 4

PRID was sum of the PID and PAR for each participant at each evaluation time point (2 hours after dosing, 4 hours after dosing). Pain Intensity was evaluated on a 4-stage scale ranges from 3=severe pain to 0=no pain and PID ranges from -3 (the worst) to +3 (the most improved). PAR ranges from 0 (no improved) to +4 (the most improved). PRID ranges from -3 (the worst) to +7 (the most improved).

Time frame:
Week 4
Reported as:
Mean · units on scale
Pain Relief Combined With Pain Intensity Difference (PRID) at Week 4
units on scaleTramadol Hydrochloride Plus Acetaminophen (JNS013)
2 hours after dosing at Week 41.3 ± 1.06
4 hours after dosing at Week 41.4 ± 1.20
SecondaryChange From Baseline in Short Form-36 (SF-36) Score

SF-36 is a metric for general health and Quality of Life (QOL), consists of 8 sub-scale indices related to health and QOL (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health). Each of the sub-scale scores ranged from 0 to 100, where higher values indicate a better health status or a better mental status.

Time frame:
Baseline, Week 4 and 52
Reported as:
Mean · units on a scale
Change From Baseline in Short Form-36 (SF-36) Score
units on a scaleTramadol Hydrochloride Plus Acetaminophen (JNS013)
Physical functioning:Baseline33.7 ± 17.03
Physical functioning:Change at Week 4 (n=150)2.9 ± 9.06
Physical functioning:Change at Week 52 (n=96)4.1 ± 12.00
Role-physical:Baseline35.0 ± 15.43
Role-physical:Change at Week 4 (n=150)3.2 ± 11.51
Role-physical:Change at Week 52 (n=96)6.0 ± 13.76
Bodily pain:Baseline33.7 ± 6.70
Bodily pain:Change at Week 4 (n=150)5.5 ± 7.12
Bodily pain:Change at Week 52 (n=96)9.0 ± 8.74
General health:Baseline42.1 ± 10.42
General health:Change at Week 4 (n=150)1.5 ± 7.74
General health:Change at Week 52 (n=96)3.9 ± 8.92
Vitality:Baseline44.0 ± 9.82
Vitality:Change at Week 4 (n=150)2.1 ± 8.37
Vitality:Change at Week 52 (n=96)4.9 ± 9.38
Social functioning:Baseline41.0 ± 13.61
Social functioning:Change at Week 4 (n=150)2.7 ± 11.36
Social functioning:Change at Week 52 (n=96)6.0 ± 11.57
Role-emotional:Baseline39.4 ± 14.97
Role-emotional:Change at Week 4 (n=150)2.6 ± 12.43
Role-emotional:Change at Week 52 (n=96)5.2 ± 14.44
Mental health:Baseline43.9 ± 11.50
Mental health:Change at Week 4 (n=150)2.5 ± 8.73
Mental health:Change at Week 52 (n=96)5.5 ± 10.11

Adverse events

Collected over From signing of informed consent until study completion (up to 54 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tramadol Hydrochloride Plus Acetaminophen (JNS013)—24/190 (12.6%)189/190 (99.5%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventTramadol Hydrochloride Plus Acetaminophen (JNS013)
VomitingGastrointestinal disorders3/190
Colon polypsGastrointestinal disorders2/190
NauseaGastrointestinal disorders2/190
BronchitisInfections and infestations1/190
GastroenteritisInfections and infestations1/190
PyelonephritisInfections and infestations1/190
Cerebral infarctionNervous system disorders1/190
Diabetic autonomic nerve neuropathyNervous system disorders1/190
DizzinessNervous system disorders1/190
Loss of consciousnessNervous system disorders1/190
Most frequent other events
Showing 10 of 243
Most frequent other events
EventTramadol Hydrochloride Plus Acetaminophen (JNS013)
NauseaGastrointestinal disorders101/190
ConstipationGastrointestinal disorders75/190
VomitingGastrointestinal disorders68/190
DizzinessNervous system disorders52/190
NasopharyngitisInfections and infestations49/190
SomnolenceNervous system disorders38/190
HeadacheNervous system disorders28/190
Weight decreasedInvestigations23/190
Gamma-glutamyltransferase increasedInvestigations21/190
Blood creatine phosphokinase increasedInvestigations19/190

Baseline characteristics

Age, Continuous
Age, Continuous(years)Tramadol Hydrochloride Plus Acetaminophen (JNS013)
Mean64.3 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)Tramadol Hydrochloride Plus Acetaminophen (JNS013)
Female106
Male84
08

Study locations

26 sites
  • Chikushi, Japan
  • Chuo, Japan
  • Fukui, Japan
  • Fukuoka, Japan
  • Hiratsuka, Japan
  • Ichikawa, Japan
  • Kashiwa, Japan
  • Komatsu, Japan
  • Kuki, Japan
  • Kumamoto, Japan
  • Kyoto, Japan
  • Mihara, Japan
  • Nagoya, Japan
  • Nerima, Japan
  • Obihiro, Japan
  • Ogi, Japan
  • Ohta-Ku, Japan
  • Osaka, Japan
  • Tagawa, Japan
  • Taito-Ku, Japan
  • Takaoka, Japan
  • Tokyo N/A, Japan
  • Tokyo, Japan
  • Urayasu, Japan
  • Yame, Japan
  • Yokohama, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Oct 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2008
First posted
Aug 18, 2008
Start
May 2008
Primary completionActual
Oct 2009
CompletionActual
Nov 2009
Results first posted
Jun 20, 2013
Last update
Jul 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00736957
Responsible party
Sponsor
First posted
Aug 18, 2008
Start date
May 2008
Primary completion
Oct 2009
Completion
Nov 2009
Results posted
Jun 20, 2013
Last update
Jul 2, 2014

Study contacts

Janssen Pharmaceutical K.K. Clinical Trial
study director · Janssen Pharmaceutical K.K.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tramadol · Acetaminophen

Start the discussion